Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025)

FGF21-Fc fusion protein · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025), covering 2024-08-26 to 2024-08-26. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) [Phase 2]

See pricing